Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    03-October-2000      
Issue 173 Next Update - 14:00 UTC 08:00 EST    04-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 03-October-2000:

Scientists have discovered that a multipurpose protein found in several bodily fluids has another important function — it can promote the healing of abnormal skin wounds, which are a significant problem in the elderly. The substance is known as SLPI and is commonly referred to as "slippy.

Patients and practitioners interested in the new research on SLPI will be interested in an ongoing clinical trial to study the substance. This study will evaluate the effects of the protein--secretory leukocyte protease inhibitor (SLPI)--on skin wound healing. Produced naturally by the body, SLPI modifies levels of elastase, a substance that breaks down the skin.

The number of people with asthma continues to rise dramatically in the United States. The disease now affects more than 17 million Americans--one third of whom are children. A new asthma treatment just approved by the FDA may help improve asthma control by enabling adults and children to use a simple breath-activated device to take a medication that helps to effectively treat their condition.

A study of several thousand licensed registered nurses in the State of Minnesota found that nurses have a high level of satisfaction in their career, but when asked if they would encourage others to go into the practice of nursing, 39.7% couldn't make the recommendation. Nearly 80% of the nurses answered no to the question, "Do you believe you will receive excellent quality care in your declining years?"

In other FDA news, the FDA has approved Fosamax®(alendronate sodium) 10 mg once daily for treatment to increase bone mass in men with osteoporosis. Fosamax is the first medicine to be indicated for men with osteoporosis. An estimated 2 million American men already have osteoporosis. It is projected that the number of men with osteoporosis will increase approximately 20 percent by the year 2015 due to the aging population. Get the prescribing information for Fosamax in today's Vidyya.

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.